A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Death Pathways

Background:

• The Bcl-2 protein family regulates apoptosis and is often deregulated in cancer, contributing to chemoresistance.
• Myeloid cell leukemia-1 (Mcl1) is an anti-apoptotic member of this family, crucial for cell survival.
• Tumor cells can develop resistance to apoptosis, impacting treatment efficacy and disease progression.

Purpose of the Study:

• To characterize a newly identified variant of the anti-apoptotic protein Mcl1 (Mcl1L) found in human neuroblastoma and leukemia cells.
• To investigate the functional and structural differences of this Mcl1L variant compared to the wild-type Mcl1L.
• To assess the impact of this variant on cell death pathways and its potential role in aggressive tumors.

Main Methods:

• Cloning of the Mcl1L variant from human cancer cell lines.
• Sequence analysis to identify deletions and altered functional domains.
• Biochemical assays to assess binding affinity to pro-apoptotic proteins (e.g., Bim).
• Functional studies evaluating anti-proliferative and anti-apoptotic activities in response to death receptor signaling.

Main Results:

• A novel Mcl1L variant, Mcl1LdelGly158-Asp172, was identified, lacking 15 conserved amino acids including a PEST sequence, phosphorylation sites, and a caspase cleavage site.
• This variant exhibited enhanced binding to the pro-apoptotic protein Bim compared to wild-type Mcl1L.
• Mcl1LdelGly158-Asp172 demonstrated increased anti-proliferative and anti-apoptotic activity, particularly during death receptor-induced apoptosis.

Conclusions:

• The Mcl1LdelGly158-Asp172 variant possesses enhanced anti-apoptotic properties.
• This variant may confer a significant survival advantage to tumor cells by more efficiently blocking extrinsic death signaling.
• The discovery suggests a novel mechanism contributing to the aggressiveness of certain tumors and potential therapeutic resistance.